Active, not recruitingPhase 1NCT05901987
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
Studying Proximal spinal muscular atrophy type 2
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GeneCradle Inc
- Intervention
- GC101(genetic)
- Enrollment
- 33 enrolled
- Eligibility
- 6-60 years · All sexes
- Timeline
- 2023 – 2025
Study locations (5)
- Peking University， First Hospital, Department of Pediatrics, Beijing, China
- Bayi Children's Hospital, Seventh Medical Center, PLA general hospital, Beijing, China
- West China Second University Hospital, Sichuan University, Chengdu, China
- Children's Hospital of Chongqing Medical University, Chongqing, China
- Tongji Medical college of Huazhong University of Science&Technology, Affiliated Children's Hospital, Wuhan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05901987 on ClinicalTrials.gov